Open tender · Germany · Contract notice
Open house Arzneimittelrabattverträge zum Wirkstoff Adalimumab, ATC L04AB04
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse in Germany is inviting bids for “Open house Arzneimittelrabattverträge zum Wirkstoff Adalimumab, ATC L04AB04”. Bids close on 31 January 2028.
The work
Open house discount contracts for the active substance Adalimumab (ATC L04AB04) for the period from 01.04.2026 to 31.03.2028.
- Contracts are non-exclusive and with all market participants
- Exclusion of pediatric medicines (Kinderarzneimittel) as per BfArM-Liste
- Submission of AMIce database extracts for all contract drugs
- Submission of supplementary proof of marketing authorization if required
Key facts
- Contract period
- max 24 months from the earliest contract start date
- Evaluation
- The tender is for a non-exclusive 'open house' model with uniform conditions, not a traditional award.
What it takes to qualify
Worth a closer look
- The tender is for a non-exclusive 'open house' model with uniform conditions, not a traditional award.
- Submission of AMIce database extracts for all contract drugs
- Submission of supplementary proof of marketing authorization if required
- The first contract award will be at least 10 calendar days after publication in the Official Journal of the European Union.
- The tender is not a public contract under the Public Procurement Directive.
- Submission of contract documents can be in handwritten or electronic form with a qualified electronic signature.
Policy conditions
No reservation, preference or local-content restriction.